Abstract
Although medication is the treatment of choice for schizophrenia, most patients continue to experience exhibit residual symptoms despite compliance. Recent studies suggest that cognitive behavioral therapy (CBT) is useful in the treatment of schizophrenia and other psychotic disorders [1]. Results of previous studies suggest that patients treated with CBT, in conjunction with medication, exhibit decreased frequency and severity of delusions, hallucinations and negative symptoms. Finally, CBT has been shown to increase medication compliance in patients with schizophrenia and bipolar disorder. Speaking of the outcome data on CBT, Weiden was recently quoted as saying, “if this were a patented drug trial, you would have heard about [these findings]” [2]. Despite the empirical evidence supporting the use of CBT in patients with schizophrenia, this treatment is relatively unknown to the psychiatric community. This article will review the mechanisms and findings associated with CBT and schizophrenia, and suggest future directions for dissemination in the psychiatric community.
Keywords: schizophrenia, cognitive behavioral therapy, dissemination
Current Pharmaceutical Design
Title: Cognitive Therapy for Schizophrenia: Treatment and Dissemination
Volume: 10 Issue: 18
Author(s): L. Marcinko and M. Read
Affiliation:
Keywords: schizophrenia, cognitive behavioral therapy, dissemination
Abstract: Although medication is the treatment of choice for schizophrenia, most patients continue to experience exhibit residual symptoms despite compliance. Recent studies suggest that cognitive behavioral therapy (CBT) is useful in the treatment of schizophrenia and other psychotic disorders [1]. Results of previous studies suggest that patients treated with CBT, in conjunction with medication, exhibit decreased frequency and severity of delusions, hallucinations and negative symptoms. Finally, CBT has been shown to increase medication compliance in patients with schizophrenia and bipolar disorder. Speaking of the outcome data on CBT, Weiden was recently quoted as saying, “if this were a patented drug trial, you would have heard about [these findings]” [2]. Despite the empirical evidence supporting the use of CBT in patients with schizophrenia, this treatment is relatively unknown to the psychiatric community. This article will review the mechanisms and findings associated with CBT and schizophrenia, and suggest future directions for dissemination in the psychiatric community.
Export Options
About this article
Cite this article as:
Marcinko L. and Read M., Cognitive Therapy for Schizophrenia: Treatment and Dissemination, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384132
DOI https://dx.doi.org/10.2174/1381612043384132 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The HAG Mechanism: A Molecular Rationale For The Therapeutic Application Of Iron Chelators In Human Diseases Involving the 2-Oxoacid Utilizing Dioxygenases
Current Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?
Current Pharmaceutical Design The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets Improvement of Abiotic Stress Tolerance of Crops Via Enhancement of their Antioxidant Capacity
Current Chemical Biology The Pim Kinases: New Targets for Drug Development
Current Drug Targets Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design The Heme-Heme Oxygenase System in Wound Healing; Implications for Scar Formation
Current Drug Targets Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Indispensable Roles of Plastids in Arabidopsis thaliana Embryogenesis
Current Genomics